|
1
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Balch C, Huang TH, Brown R and Nephew KP:
The epigenetics of ovarian cancer drug resistance and
resensitization. Am J Obstet Gynecol. 191:1552–1572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Novik KL, Nimmrich I, Genc B, Maier S,
Piepenbrock C, Olek A and Beck S: Epigenomics: genome-wide study of
methylation phenomena. Curr Issues Mol Biol. 4:111–28.
2002.PubMed/NCBI
|
|
4
|
Lund AH and van Lohuizen M: Epigenetics
and cancer. Genes Dev. 18:2315–2335. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seeber LM and van Diest PJ: Epigenetics in
ovarian cancer. Methods Mol Biol. 863:253–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Widschwendter M, Jiang G, Woods C, Müller
HM, Fiegl H, Goebel G, Marth C, Müller-Holzner E, Zeimet AG, Laird
PW and Ehrlich M: DNA hypomethylation and ovarian cancer biology.
Cancer Res. 64:4472–4480. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang B, Kirov S and Snoddy J: WebGestalt:
an integrated system for exploring gene sets in various biological
contexts. Nucleic Acids Res. 33(Web Server issue): W741–W748. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C
and Jensen LJ: STRING v9.1: Protein-protein interaction networks,
with increased coverage and integration. Nucleic Acids Res.
41(Database issue): D808–D815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eyre R, Harvey I, Stemke-Hale K, Lennard
TW, Tyson-Capper A and Meeson AP: Reversing paclitaxel resistance
in ovarian cancer cells via inhibition of the ABCB1 expressing side
population. Tumour Biol. 35:9879–9892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hatle KM, Neveu W, Dienz O, Rymarchyk S,
Barrantes R, Hale S, Farley N, Lounsbury KM, Bond JP, Taatjes D and
Rincón M: Methylation-controlled J protein promotes c-Jun
degradation to prevent ABCB1 transporter expression. Mol Cell Biol.
27:2952–66. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee PS, Teaberry VS, Bland AE, et al:
Elevated MAL expression is accompanied by promoter hypomethylation
and platinum resistance in epithelial ovarian cancer. Int J Cancer.
126:1378–1389. 2010.PubMed/NCBI
|
|
12
|
Harvey I, Stemke-Hale K, Lennard TW,
Tyson-Capper A and Meeson AP: Reversing paclitaxel resistance in
ovarian cancer cells via inhibition of the ABCB1 expressing side
population. Tumour Biol. 35:9879–9892. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Watanabe Y, Ueda H, Etoh T, Koike E,
Fujinami N, Mitsuhashi A and Hoshiai H: A change in promoter
methylation of hMLH1 is a cause of acquired resistance to
platinum-based chemotherapy in epithelial ovarian cancer.
Anticancer Res. 27:1449–1452. 2007.PubMed/NCBI
|
|
14
|
Gifford G, Paul J, Vasey PA, Kaye SB and
Brown R: The acquisition of hMLH1 methylation in plasma DNA after
chemotherapy predicts poor survival for ovarian cancer patients.
Clin Cancer Res. 10:4420–4426. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stordal B, Timms K, Farrelly A, Gallagher
D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, et
al: BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only
one functionally deleterious BRCA1 mutation. Mol Oncol. 7:567–579.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang YQ, Zhang JR, Li SD, He YY, Yang YX,
Liu XL and Wan XP: Aberrant methylation of breast and ovarian
cancer susceptibility gene 1 in chemosensitive human ovarian cancer
cells does not involve the phosphatidylinositol 3′-kinase-Akt
pathway. Cancer Sci. 101:1618–1623. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chou JL, Su HY, Chen LY, Liao YP,
Hartman-Frey C, Lai YH, Yang HW, Deatherage DE, Kuo CT, Huang YW,
et al: Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4
target gene and tumor suppressor, is associated with poor prognosis
in human ovarian cancer. Lab Invest. 90:414–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strathdee G, Vass JK, Oien KA, Siddiqui N,
Curto-Garcia J and Brown R: Demethylation of the MCJ gene in stage
III/IV epithelial ovarian cancer and response to chemotherapy.
Gynecol Oncol. 97:898–903. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Strathdee G, Davies BR, Vass JK, Siddiqui
N and Brown R: Cell type-specific methylation of an intronic CpG
island controls expression of the MCJ gene. Carcinogenesis.
25:693–701. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao X, Hu JF, Li T, Yang Y, Sun Z, Ulaner
GA, Vu TH and Hoffman AR: Epigenetic regulation of the taxol
resistance-associated gene TRAG-3 in human tumors. Cancer Genet
Cytogenet. 151:1–13. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baba T, Convery PA, Matsumura N, Whitaker
RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al:
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian
cancer cells. Oncogene. 28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nicholson LJ, Smith PR, Hiller L,
Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A, Schmid
P and Crook T: Epigenetic silencing of argininosuccinate synthetase
confers resistance to platinum-induced cell death but collateral
sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer.
125:1454–1463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vos MD, Martinez A, Elam C, Dallol A,
Taylor BJ, Latif F and Clark GJ: A role for the RASSF1A tumor
suppressor in the regulation of tubulin polymerization and genomic
stability. Cancer Res. 64:4244–4250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kassler S, Donninger H, Birrer MJ and
Clark GJ: RASSF1A and the Taxol response in ovarian cancer. Mol
Biol Int. 2012:2632672012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blanco-Aparicio C, Renner O, Leal JF and
Carnero A: PTEN, more than the AKT pathway. Carcinogenesis.
28:1379–1386. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai F, Zhang Y, Zhu X, Shan N and Chen Y:
Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial
ovarian carcinoma cells through regulation of PTEN methylation.
Target Oncol. 7:217–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Horak P, Pils D, Haller G, Pribill I,
Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C and
Krainer M: Contribution of epigenetic silencing of tumor necrosis
factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL
resistance and ovarian cancer. Mol Cancer Res. 3:335–343. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Hu W, Shen DY, Kavanagh JJ and Fu S:
Azacitidine enhances sensitivity of platinum-resistant ovarian
cancer cells to carboplatin through induction of apoptosis. Am J
Obstet Gynecol. 200(177): e1–e9. 2009.
|
|
30
|
Bram EE, Hu W, Shen DY, Kavanagh JJ and Fu
S: Chemotherapeutic drug-induced ABCG2 promoter demethylation as a
novel mechanism of acquired multidrug resistance. Neoplasia.
11:1359–1370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park ST, Byun HJ, Kim BR, Dong SM, Park
SH, Jang PR and Rho S: Tumor suppressor BLU promotes paclitaxel
antitumor activity by inducing apoptosis through the
down-regulation of Bcl-2 expression in tumorigenesis. Biochem
Biophys Res Commun. 435:153–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chiang YC, Chang MC, Chen PJ, Wu MM, Hsieh
CY, Cheng WF and Chen CA: Epigenetic silencing of BLU through
interfering apoptosis results in chemoresistance and poor prognosis
of ovarian serous carcinoma patients. Endocr Relat Cancer.
20:213–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang N, Zhang H, Yao Q, Wang Y, Dai S and
Yang X: TGFBI promoter hypermethylation correlating with paclitaxel
chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 31:62012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ali MW, Cacan E, Liu Y, Pierce JY,
Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF and Hooks
SB: Transcriptional suppression, DNA methylation and histone
deacetylation of the regulator of G-protein signaling 10 (RGS10)
gene in ovarian cancer cells. PLoS One. 8:e601852013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okochi-Takada E, Nakazawa K, Wakabayashi
M, Mori A, Ichimura S, Yasugi T and Ushijima T: Silencing of the
UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer.
119:1338–1344. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jin C, Yu W, Lou X, Zhou F, Han X, Zhao N
and Lin B: UCHL1 is a putative tumor suppressor in ovarian cancer
cells and contributes to cisplatin resistance. J Cancer. 4:662–670.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
He X, Khurana A, Roy D, Kaufmann S and
Shridhar V: Loss of HSulf-1 expression enhances tumorigenicity by
inhibiting Bim expression in ovarian cancer. Int J Cancer.
135:1783–1789. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lai J, Chien J, Staub J, Avula R, Greene
EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR and Shridhar V:
Loss of HSulf-1 up-regulates heparin-binding growth factor
signaling in cancer. J Biol Chem. 278:23107–23117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Su HY, Lai HC, Lin YW, Liu CY, Chen CK,
Chou YC, Lin SP, Lin WC, Lee HY and Yu MH: Epigenetic silencing of
SFRP5 is related to malignant phenotype and chemoresistance of
ovarian cancer through Wnt signaling pathway. Int J Cancer.
127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao S, Zhao X, Lin B, Hu Z, Yan L and Gao
J: Clinical implications of REST and TUBB3 in ovarian cancer and
its relationship to paclitaxel resistance. Tumour Biol.
33:1759–1765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Izutsu N, Maesawa C, Shibazaki M, Oikawa
H, Shoji T, Sugiyama T and Masuda T: Epigenetic modification is
involved in aberrant expression of class III beta-tubulin, TUBB3,
in ovarian cancer cells. Int J Oncol. 32:1227–1235. 2008.PubMed/NCBI
|
|
42
|
Pattamadilok J, Huapai N, Rattanatanyong
P, Vasurattana A, Triratanachat S, Tresukosol D and Mutirangura A:
LINE-1 hypomethylation level as a potential prognostic factor for
epithelial ovarian cancer. Int J Gynecol Cancer. 18:711–717. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Litkouhi B, Kwong J, Lo CM, Smedley JG
III, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, et
al: Claudin-4 overexpression in epithelial ovarian cancer is
associated with hypomethylation and is a potential target for
modulation of tight junction barrier function using a C-terminal
fragment of Clostridium perfringens enterotoxin. Neoplasia.
9:304–314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin X, Shang X, Manorek G and Howell SB:
Regulation of the Epithelial-Mesenchymal Transition by Claudin-3
and Claudin-4. PLoS One. 8:e674962013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shang X, Lin X, Alvarez E, Manorek G and
Howell SB: Tight junction proteins claudin-3 and claudin-4 control
tumor growth and metastases. Neoplasia. 14:974–985. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shang X, Lin X, Manorek G and Howell SB:
Claudin-3 and claudin-4 regulate sensitivity to cisplatin by
controlling expression of the copper and cisplatin influx
transporter CTR1. Mol Pharmacol. 83:85–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jiang Y, Chu Y, Tang W, Wan Y, Zhang L and
Cheng W: Transcription factor WT1 and promoter CpG hypomethylation
coactivate HOXA10 expression in ovarian cancer. Curr Pharm Des.
20:1647–1654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Matei D, Fang F, Shen C, Schilder J,
Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP: Epigenetic
resensitization to platinum in ovarian cancer. Cancer Res.
72:2197–2205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N
and Feng Y: HOXA10 is overexpressed in human ovarian clear cell
adenocarcinoma and correlates with poor survival. Int J Gynecol
Cancer. 19:1347–1352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Widschwendter M, Apostolidou S, Jones AA,
Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M,
Cibula D, et al: HOXA methylation in normal endometrium from
premenopausal women is associated with the presence of ovarian
cancer: a proof of principle study. Int J Cancer. 125:2214–2218.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fiegl H, Windbichler G, Mueller-Holzner E,
Goebel G, Lechner M, Jacobs IJ and Widschwendter M: HOXA11 DNA
methylation - a novel prognostic biomarker in ovarian cancer. Int J
Cancer. 123:725–729. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Taniguchi T, Tischkowitz M, Ameziane N,
Hodgson SV, Mathew CG, Joenje H, Mok SC and D'Andrea AD: Disruption
of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian
tumors. Nat Med. 9:568–574. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y,
Zhu Y and Wang Z: The role of the PTEN/PI3K/Akt pathway on
prognosis in epithelial ovarian cancer: a meta-analysis.
Oncologist. 19:528–535. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chu EC and Tarnawski AS: PTEN regulatory
functions in tumor suppression and cell biology. Med Sci Monit.
10:RA235–RA241. 2004.PubMed/NCBI
|
|
55
|
Lee S, Choi EJ, Jin C and Kim DH:
Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA
amplification contributes to cisplatin resistance in an ovarian
cancer cell line. Gynecol Oncol. 97:26–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wu H, Cao Y, Weng D, Xing H, Song X, Zhou
J, Xu G, Lu Y, Wang S and Ma D: Effect of tumor suppressor gene
PTEN on the resistance to cisplatin in human ovarian cancer cell
lines and related mechanisms. Cancer Lett. 271:260–271. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sui H, Fan ZZ and Li Q: Signal
transduction pathways and transcriptional mechanisms of
ABCB1/Pgp-mediated multiple drug resistance in human cancer cells.
J Int Med Res. 40:426–435. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Krishnamurthy P and Schuetz JD: Role of
ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol.
46:381–410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen Y, Bieber MM and Teng NN: Hedgehog
signaling regulates drug sensitivity by targeting ABC transporters
ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog.
53:625–634. 2014.PubMed/NCBI
|
|
60
|
Schneider J, Jimenez E, Marenbach K, Marx
D and Meden H: Co-expression of the MDR1 gene and HSP27 in human
ovarian cancer. Anticancer Res. 18:2967–2971. 1998.PubMed/NCBI
|
|
61
|
Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan
HY: Differential DNA methylation profiles in gynecological cancers
and correlation with clinico-pathological data. BMC Cancer.
6:2122006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Swisher EM, Gonzalez RM, Taniguchi T,
Garcia RL, Walsh T, Goff BA and Welcsh P: Methylation and protein
expression of DNA repair genes: association with chemotherapy
exposure and survival in sporadic ovarian and peritoneal
carcinomas. Mol Cancer. 8:482009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kang S, Dong SM and Park NH: Frequent
promoter hypermethylation of TGFBI in epithelial ovarian cancer.
Gynecol Oncol. 118:58–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ignatov T, Eggemann H, Costa SD, Roessner
A, Kalinski T and Ignatov A: BRCA1 promoter methylation is a marker
of better response to platinum-taxane-based therapy in sporadic
epithelial ovarian cancer. J Cancer Res Clin Oncol. 140:1457–1463.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
de Ibanez Caceres I, Battagli C, Esteller
M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg
BL and Cairns P: Tumor cell-specific BRCA1 and RASSF1A
hypermethylation in serum, plasma and peritoneal fluid from ovarian
cancer patients. Cancer Res. 64:6476–6481. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhang H, Zhang S, Cui J, Zhang A, Shen L
and Yu H: Expression and promoter methylation status of mismatch
repair gene hMLH1 and hMSH2 in epithelial ovarian cancer. Aust N Z
J Obstet Gynaecol. 48:505–509. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Fang F, Balch C, Schilder J, Breen T,
Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP and Matei
DE: A phase 1 and pharmacodynamic study of decitabine in
combination with carboplatin in patients with recurrent,
platinum-resistant, epithelial ovarian cancer. Cancer.
116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bhagat R, Chadaga S, Premalata CS, Ramesh
G, Ramesh C, Pallavi VR and Krishnamoorthy L: Aberrant promoter
methylation of the RASSF1A and APC genes in epithelial ovarian
carcinoma development. Cell Oncol (Dordr). 35:473–479. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bondurant AE, Huang Z, Whitaker RS, Simel
LR, Berchuck A and Murphy SK: Quantitative detection of RASSF1A DNA
promoter methylation in tumors and serum of patients with serous
epithelial ovarian cancer. Gynecol Oncol. 123:581–587. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ma L, Zhang JH, Liu FR and Zhang X:
Hypermethylation of promoter region of RASSF1A gene in ovarian
malignant epithelial tumors. Zhonghua Zhong Liu Za Zhi. 27:657–659.
2005.(In Chinese). PubMed/NCBI
|
|
71
|
Liggett TE, Melnikov A, Yi Q, Replogle C,
Hu W, Rotmensch J, Kamat A, Sood AK and Levenson V: Distinctive DNA
methylation patterns of cell-free plasma DNA in women with
malignant ovarian tumors. Gynecol Oncol. 120:113–120. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Shen Y, Shen R, Ge L, Zhu Q and Li F:
Fibrillar type I collagen matrices enhance metastasis/invasion of
ovarian epithelial cancer via β1 integrin and PTEN signals. Int J
Gynecol Cancer. 22:1316–1324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Qiao YH, Cheng J and Guo RX: Expression of
phosphorylated protein kinase B and PTEN protein in ovarian
epithelial cancer. Zhonghua Fu Chan Ke Za Zhi. 42:325–329. 2007.(In
Chinese). PubMed/NCBI
|
|
74
|
Che Y, Yao Q, Dai S, Luo B and Wang Y:
Study of the mutation and expression of PTEN gene in endometrial
carcinoma and epithelial ovarian cancer. Zhonghua Fu Chan Ke Za
Zhi. 37:608–611. 2002.(In Chinese). PubMed/NCBI
|
|
75
|
Dong HP, Kleinberg L, Silins I, Flørenes
VA, Tropé CG, Risberg B, Nesland JM and Davidson B: Death receptor
expression is associated with poor response to chemotherapy and
shorter survival in metastatic ovarian carcinoma. Cancer.
112:84–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman
RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et
al: Phase 1b-2a study to reverse platinum resistance through use of
a hypomethylating agent, azacitidine, in patients with
platinum-resistant or platinum-refractory epithelial ovarian
cancer. Cancer. 117:1661–1669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Brait M, Maldonado L, Noordhuis MG, Begum
S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C, et
al: Association of promoter methylation of VGF and PGP9.5 with
ovarian cancer progression. PLoS One. 8:e708782013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Al-Shabanah OA, Hafez MM, Hassan ZK,
Sayed-Ahmed MM, Abozeed WN, Alsheikh A and Al-Rejaie SS:
Methylation of SFRPs and APC genes in ovarian cancer infected with
high risk human papillomavirus. Asian Pac J Cancer Prev.
15:2719–2725. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Saran U, Arfuso F, Zeps N and Dharmarajan
A: Secreted frizzled-related protein 4 expression is positively
associated with responsiveness to cisplatin of ovarian cancer cell
lines in vitro and with lower tumour grade in mucinous ovarian
cancers. BMC Cell Biol. 13:252012. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Berchuck A, Iversen ES, Luo J, Clarke JP,
Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, et
al: Microarray analysis of early stage serous ovarian cancers shows
profiles predictive of favorable outcome. Clin Cancer Res.
15:2448–2455. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Raspaglio G, Petrillo M, Martinelli E, Li
Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei
S, Zannoni GF, et al: Sox9 and Hif-2α regulate TUBB3 gene
expression and affect ovarian cancer aggressiveness. Gene.
542:173–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Tanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L
and Teixeira JM: PTEN loss and HOXA10 expression are associated
with ovarian endometrioid adenocarcinoma differentiation and
progression. Carcinogenesis. 34:893–901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Dhillon VS, Shahid M and Husain SA: CpG
methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in
Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer.
3:332004. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Materna V, Surowiak P, Kaplenko I,
Spaczyński M, Duan Z, Zabel M, Dietel M and Lage H:
Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is
predictive for clinical outcome in ovarian carcinoma patients.
Virchows Arch. 450:187–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Su HY, Lai HC, Lin YW, Chou YC, Liu CY and
Yu MH: An epigenetic marker panel for screening and prognostic
prediction of ovarian cancer. Int J Cancer. 124:387–393. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Lum E, Vigliotti M, Banerjee N, Cutter N,
Wrzeszczynski KO, Khan S, Kamalakaran S, Levine DA, Dimitrova N and
Lucito R: Loss of DOK2 induces carboplatin resistance in ovarian
cancer via suppression of apoptosis. Gynecol Oncol. 130:369–376.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Karaca B, Atmaca H, Bozkurt E, Kisim A,
Uzunoglu S, Karabulut B, Sezgin C, Sanli UA and Uslu R: Combination
of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis
and modulating epigenetics in human ovarian cancer cells. Mol Biol
Rep. 40:3925–3933. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Lawen A: Apoptosis - an introduction.
Bioessays. 25:888–896. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Singh M, Chaudhry P, Fabi F and Asselin E:
Cisplatin-induced caspase activation mediates PTEN cleavage in
ovarian cancer cells: a potential mechanism of chemoresistance. BMC
Cancer. 13:2332013. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Strathdee G, MacKean MJ, Illand M and
Brown R: A role for methylation of the hMLH1 promoter in loss of
hMLH1 expression and drug resistance in ovarian cancer. Oncogene.
18:2335–2341. 1999. View Article : Google Scholar : PubMed/NCBI
|
